You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

284 Results
Drug
Other Name(s): Qinlock™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2026
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    ripretinib - For adult patients with advanced gastrointestinal stromal tumours (GIST) who have progression on or intolerance to imatinib, sunitinib and regorafenib
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ripretinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2025
Guidelines and Advice
Status: In-Review
ID: 24-3
Version: 2
Dec 2016
Regimen
Cancer Type:
Gastrointestinal, 
Anus
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
retifanlimab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2026
Drug
Other Name(s): Orgovyx®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Feb 2026
Drug
Other Name(s): Voranigo™
Quick Link(s):
Drug Monograph
New
Mar 2026
Regimen
Cancer Type:
Central Nervous System
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    vorasidenib - For the treatment of Grade 2 astrocytoma or oligodendroglioma in patients with a susceptible IDH1 mutation or IDH2 mutation following surgery, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
vorasidenib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Mar 2026

Pages